Industry News Eli Lilly / Stipple Bio BioSpace

Lilly pays for tumor-selective binders: up to $5.9B Stipple oncology pact

  • Lilly gets exclusive worldwide rights to oncology products from Stipple Bio's Pointillist platform, which finds binders to tumor-specific epitopes on cell-surface proteins.
  • Terms: an undisclosed upfront plus an equity investment in Stipple, and up to $5.9B in development and commercial milestones.
  • Lilly announced it alongside the Calytrix buyout, funding pipeline-building from incretin cash.
Points Based on public reports

The headline figure is almost all milestones, so the real signal is the equity stake and exclusivity, not the $5.9B. The platform targets on-target, off-tumor toxicity, which is where many bispecifics and ADCs stumble; no target is named, so Lilly is buying a method before a molecule. Compare how Lilly pairs small early-stage buyouts with option-style platform deals: it is spreading oncology bets cheaply while the incretin franchise pays.